SCHEMBL6183335

SCHEMBL6183335

O=C1NC(=O)C(=Cc2ccc(-c3cccc(C(=O)NCc4ccccc4)c3)cc2)S1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
EPHX2 P34913 1/20 0.55
NR1H4 Q96RI1 1/20 0.55
CFD P00746 1/20 0.54
ERN1 O75460 1/20 0.53
PTPN1 P18031 4/20 0.53
HPGD P15428 4/20 0.52
SENP1 Q9P0U3 2/20 0.49
SENP2 Q9HC62 1/20 0.49
PIM1 P11309 1/20 0.49
PIM3 Q86V86 1/20 0.49
PIM2 Q9P1W9 1/20 0.49
PIK3CG P48736 1/20 0.48
JAK2 O60674 1/20 0.48
MAP4K4 O95819 1/20 0.48
CHEK2 O96017 1/20 0.48
PRKCG P05129 1/20 0.48
CDK1 P06493 1/20 0.48
FES P07332 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183331 1.00 MAOA (0.56) MAOAMAOBEPHX2NR1H4CFD
SCHEMBL6184236 0.94 MAOA (0.53) MAOAMAOBCFDPTPN1HPGD
SCHEMBL6184231 0.94 MAOA (0.53) MAOAMAOBCFDPTPN1HPGD
SCHEMBL22777148 0.87 MAOA (0.65) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL22777150 0.87 MAOA (0.65) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL5386765 0.85 MAOA (0.54) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL5386774 0.85 MAOA (0.54) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL6204803 0.82 MAOA (0.55) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL6204806 0.82 MAOA (0.55) MAOAMAOBPTPN1HPGDPIM1
SCHEMBL6184899 0.82 PIK3CG (0.67) MAOAMAOBHPGDPIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD MAOA 719/4885MAOB 1148/4885EPHX2 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.